Standard stepwise therapy for overactive bladder (OAB) begins with conservative therapies such as lifestyle interventions and behavioral approaches. Medications—anticholinergics or beta-3 agonists—are ...

Objective: The objective of this study was tocompare 1-year total healthcare costs for patientswith overactive bladder (OAB) initiating treatmentwith extended-release formulations of tolterodineand ...

New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA® (vibegron) 75 mg provided additional insight into the long-term effects of the product. These data were featured in podium ...

The approval was based on data from the pivotal phase 3 EMPOWUR study. The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron; Urovant Sciences) for the treatment of overactive ...

Urovant Sciences, Inc., and Holly Robinson Peete Collaborate to Bring Awareness to Overactive Bladder (OAB) Symptoms and Management Options as Part of the Time To Go™ Campaign Holly Robinson Peete ...

Tachykinins such as substance P (an agonist of NK-1, neurokinin receptor 1) are neurotransmitters involved in the micturition reflex, which suggests that NK-1 antagonists might be an effective ...

Overactive bladder is a long-term condition that won’t go away on its own and may worsen if a person does not get treatment. The condition can be caused by issues in how the brain and bladder ...

CLEVELAND, Ohio (March 1, 2023)—Approximately 33% of American women will experience overactive bladder syndrome (OAB), which interferes with daily activities, social functioning, and sleep quality.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The novel muscarinic M3 receptor antagonist DA8010 ...

The authors concluded, “Of the available treatment options examined in this study, onabotulinumtoxinA was the most cost-effective for management of overactive bladder in patients who have inadequate ...

Prostate cancer survivorship research focuses largely on oncological outcome; however, fewer studies are available that assess the effects of prostate cancer and its treatment on bladder function.